These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31496045)

  • 1. Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints.
    Kakizume T; Zhang F; Kawasaki Y; Daimon T
    Pharm Stat; 2020 Jan; 19(1):71-83. PubMed ID: 31496045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized Bayesian optimal phase II design with binary endpoint.
    Ding Y
    J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
    Waleed M; He J; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints.
    Shi H; Yin G
    Biometrics; 2018 Sep; 74(3):1055-1064. PubMed ID: 29466612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
    Yu Z; Ramakrishnan V; Meinzer C
    J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
    Guo B; Liu S
    Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian sample size determination in a three-arm non-inferiority trial with binary endpoints.
    Tang N; Yu B
    J Biopharm Stat; 2022 Sep; 32(5):768-788. PubMed ID: 35213275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian optimal phase II designs with dual-criterion decision making.
    Zhao Y; Li D; Liu R; Yuan Y
    Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.
    Whitehead J; Cleary F; Turner A
    Stat Med; 2015 May; 34(12):2048-61. PubMed ID: 25765252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomes.
    Turner RM; Clements MN; Quartagno M; Cornelius V; Cro S; Ford D; Tweed CD; Walker AS; White IR
    Stat Med; 2023 Apr; 42(8):1127-1138. PubMed ID: 36661242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian methods for the design and interpretation of clinical trials in very rare diseases.
    Hampson LV; Whitehead J; Eleftheriou D; Brogan P
    Stat Med; 2014 Oct; 33(24):4186-201. PubMed ID: 24957522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian group sequential design for a multiple arm randomized clinical trial.
    Rosner GL; Berry DA
    Stat Med; 1995 Feb; 14(4):381-94. PubMed ID: 7746978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Bayesian guidelines for phase IIB clinical trials.
    Thall PF; Simon R
    Biometrics; 1994 Jun; 50(2):337-49. PubMed ID: 7980801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.